

FONTES et al.
Appl. No. 10/521,239
Atty. Ref.: 3665-132
Amendment
Monday, March 24, 2008

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

Claims 1-22. (Canceled)

23. (Currently Amended) A method for the treatment of Charcot-Marie-Tooth disease peripheral neuropathies, comprising administering to a subject affected by or presenting a risk of developing such diseasepathology, an effective amount of vitamin C or a derivative thereofcAMP modulator.

Claims 24-28. (Canceled)

29. (Currently Amended) The method according to claim 23, wherein said Charcot-Marie-Tooth disease is for the treatment of type I Charcot-MarieTooth disease (CMTI).

Claim 30. (Canceled)

31. (Currently Amended) The method according to claim 23, wherein the vitamin C cAMP modulator is selected [[in]]from the group consisting of natural vitamin C, synthetic vitamin C and a mixture thereof.

32. (Currently Amended) The method according to claim 23, wherein the vitamin C derivative cAMP modulator is selected [[in]]from the group consisting of vitamin C salts and esters.

33. (Currently Amended) The method according to claim 23, wherein the vitamin C derivative cAMP modulator is a vitamin C derivative selected [[in]]from the group consisting of ascorbyl palmitate, dipalmitate L-ascorbate, and their mixture or in the

FONTES et al.
Appl. No. 10/521,239
Atty. Ref.: 3665-132
Amendment
Monday, March 24, 2008

~~group consisting of a glycosylated derivatives of ascorbic acid, a mannosylated derivatives of ascorbic acid, a fructosylated derivatives of ascorbic acid, a fucosylated derivatives of ascorbic acid, a galactosylated derivatives of ascorbic acid, a N-acetylglucosaminated derivatives of ascorbic acid, a N-acetylmuramic derivative[[s]] of ascorbic acid and [[their]] mixtures thereof, preferably ascorbyl-2-glucoside, 2-O-alpha-D-glucopyranosyl ascorbic acid or 6-O-beta-D-galactopyranosyl L-ascorbic acid.~~

34. (Currently Amended) The method according to claim 23, wherein ~~the vitamin C derivative cAMP modulator is a vitamin C derivative selected in the group consisting of the metal salt[[s]] of phosphorylated ascorbic acid, in particular the alkaline metal ascorbyl phosphates, the alkaline earth metal ascorbyl phosphates and the transition metal ascorbyl phosphates, preferably magnesium ascorbyl phosphate or else the ascorbyl sulfates.~~

Claims 35-44. (Canceled)

45. (new) The method according to claim 23, wherein the vitamin C derivative is selected in the group consisting of ascorbyl-2 glucoside, 2-O-alpha-D-glucopyranosyl ascorbic acid and 6-O-beta-D-galactopyranosyl L-ascorbic acid.

46. (new) The method according to claim 23, wherein the vitamin C derivative is a magnesium ascorbyl phosphate.

FONTES et al.
Appl. No. 10/521,239
Atty. Ref.: 3665-132
Amendment
Monday, March 24, 2008

47. (new) The method according to claim 23, wherein the vitamin C or a derivative thereof selected in the group consisting of vitamin C salts and esters is used as the therapeutically active ingredient.

48. (new) The method according to claim 23, wherein the vitamin C or a derivative thereof is administered to a human in need of such treatment in unit doses comprising from 1 g to 6 grams of vitamin C or a derivative thereof.

49. (new) The method according to claim 34, wherein the vitamin C derivative is an alkaline metal ascorbyl phosphates, an alkaline earth metal ascorbyl phosphates or a transition metal ascorbyl phosphates.

50. (new) The method according to claim 49, wherein the vitamin C derivative is an ascorbyl sulfates.